---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-008733"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2026-03-18T23:59:59+00:00"
generated_at: "2026-05-15T09:52:20.844389+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Genprex announces positive preclinical data for Reqorsa at AACR 2026

## Summary
- TROP2 and PTEN identified as potential biomarkers of primary resistance to TUSC2 gene therapy; 50% of NSCLC cell lines resistant.
- Reqorsa plus alectinib achieved 79% tumor shrinkage in ALK+ sensitive model, 23% improvement vs alectinib alone.
- In alectinib-resistant model, Reqorsa + alectinib produced synergistic tumor reduction and improved overall survival (p=0.0001).
- TUSC2 restoration enhanced NK cell cytotoxicity; 67% of Tusc2 KO mice and 33% of wild-type mice achieved complete tumor regression.
- Findings support progression toward clinical trials for ALK+ NSCLC and biomarker-guided patient selection.

## SEC filing metadata
- accession: 0001437749-26-008733
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2026-03-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774926008733/0001437749-26-008733-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774926008733/gnpx20260316_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-008733
- JSON: https://secwatch.observer/filing/0001437749-26-008733.json
- Plain text: https://secwatch.observer/filing/0001437749-26-008733.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.